Renewable and Specific Affinity Reagents for Mapping Proteoforms in Human Tissues

用于绘制人体组织中蛋白质组图谱的可再生特异性亲和试剂

基本信息

  • 批准号:
    9894469
  • 负责人:
  • 金额:
    $ 59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-15 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Abstract The mapping of healthy human tissue is an ongoing challenge, critical to which is understanding the cellular distribution and composition of biomolecules. Among these biomolecules, proteins are perhaps the least regularized and deeply understood, with their myriad proteoforms created within cells of distinct types. Here, we outline a new measurement framework poised to better illuminate the underlying cell types and structure defining solid tissues types in human health and wellness. We propose a two-step process that identifies and characterizes selected proteins within cells of human tissue and offers the HuBMAP Consortium highly validated and renewable affinity reagents in the process. Step 1 involves the rapid deployment of previously developed, recombinant affinity reagents (rABs) and the precise characterization of whole proteoforms in human colon tissue recognized by them. Step 2 involves the creation of “smart” probes that work on specific post-translational modifications (PTMs) in a ‘proteoform-aware’ fashion. The result will be specific, renewable and extremely validated affinity probes that are readily disseminated for use by HuBMAP Tissue Mapping Centers (TMCs). Importantly, these recombinant antibodies (rABs) will be among the most characterized of any in terms of their molecular recognition by the end of the three year granting period. This is because of the kind of low-bias readout that employs “top-down” mass spectrometry (TDMS) to interrogate whole proteoforms and their PTMs directly (no proteolysis prior to mass spectrometry). The direct deliverable of this activity will be 30 affinity reagents (20 simple and 10 smart rABs that recognize PTMs) and hundreds of characterized proteoforms to key targets of high interest to HuBMAP. The affinity reagents that emerge will be in a recombinant and renewable form (i.e., proven to express in E. coli) that are ready for use in a variety of imaging modalities through conjugation to fluorescent probes. These will be applicable to immunofluorescence by confocal microscopy, imaging CyTOF (MIBI), and DNA-barcoded antibodies to name a few. The stringent process of development and validation represents a general approach to better map both the chemical space of proteins and their spatial distribution in tissue at cellular and sub- cellular resolution. Our combined platform focuses on the biologically active forms of proteins (proteoforms) and the PTMs decorating them that maintain health and wellness in the human body. PTM maps enabled by smart and renewable reagents represent a high value outcome, templated here through this collaborative effort between the Wells and Kelleher laboratories both coordinating effectively with each other and the HuBMAP Consortium.
摘要 绘制健康人体组织图是一项持续的挑战,关键是了解细胞 生物分子的分布和组成。在这些生物分子中,蛋白质可能是最少的 规律化和深入理解,它们的无数蛋白质形式在不同类型的细胞中产生。在这里,我们 勾勒出一个新的测量框架,以便更好地阐明基本的单元类型和结构定义 人体健康中的固体组织类型。我们提出了一个分两步进行的过程,即确定和 鉴定人体组织细胞内的选定蛋白质,并为HuBMAP联盟提供高度验证的 以及在此过程中的可再生亲和试剂。步骤1涉及快速部署先前开发的、 重组亲和试剂(RABS)及其在人结肠组织中全蛋白的精确鉴定 得到了他们的认可。步骤2涉及创建工作于特定翻译后处理的“智能”探测器 以蛋白质形式感知的方式进行修饰(PTM)。结果将是具体的、可再生的和极端的 经过验证的亲和探针,易于传播,供HuBMAP组织图谱中心(TMC)使用。 重要的是,这些重组抗体(RAB)将是任何重组抗体中最具特征的抗体之一 在三年授权期结束前进行分子识别。这是因为这种低偏置读出 它使用“自上而下”的质谱学(Tdms)来直接询问整个蛋白质形式及其ptm。 (在质谱学之前没有蛋白质分解)。 这项活动的直接交付将是30种亲和试剂(20种简单的和10种识别的智能RAB PTMS)和数百个HuBMAP高度关注的关键靶标的特征蛋白形式。亲和力 出现的试剂将以重组和可再生的形式(即已被证明在大肠杆菌中表达) 通过与荧光探针的结合,可用于各种成像方式。这些将是 适用于共聚焦显微镜、细胞荧光成像(MIBI)和DNA条码的免疫荧光 举几个例子,抗体。严格的开发和验证过程代表了一种通用的方法 为了更好地绘制蛋白质的化学空间及其在细胞和亚细胞组织中的空间分布 细胞分辨率。我们的联合平台专注于具有生物活性的蛋白质形式(蛋白质形式)和 PTM装饰它们,保持人体的健康和健康。SMART支持的PTM地图 可再生试剂代表着高价值的成果,通过这种合作努力在这里建立了模板 Wells和Kelleher实验室之间的有效协调以及HuBMAP 财团。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NEIL L KELLEHER其他文献

NEIL L KELLEHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NEIL L KELLEHER', 18)}}的其他基金

Chemistry of Life Processes Predoctoral Training Program
生命过程化学博士前培训项目
  • 批准号:
    10628231
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
Multi-Omics And Synbio Enabled Discovery Of Antifungal Fernene Triterpenes
多组学和 Synbio 发现抗真菌蕨烯三萜
  • 批准号:
    10601431
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
Defining native proteoform landscape for amyloid-beta in Alzheimers disease
定义阿尔茨海默病中β淀粉样蛋白的天然蛋白质形态
  • 批准号:
    9803611
  • 财政年份:
    2019
  • 资助金额:
    $ 59万
  • 项目类别:
Renewable and Specific Affinity Reagents for Mapping Proteoforms in Human Tissues
用于绘制人体组织中蛋白质组图谱的可再生特异性亲和试剂
  • 批准号:
    10249071
  • 财政年份:
    2019
  • 资助金额:
    $ 59万
  • 项目类别:
National Resource for Translational and Developmental Proteomics
国家转化和发育蛋白质组学资源
  • 批准号:
    9456539
  • 财政年份:
    2017
  • 资助金额:
    $ 59万
  • 项目类别:
Mapping and Understanding Production of Natural Products in Fungi
绘制和了解真菌天然产物的生产
  • 批准号:
    10677824
  • 财政年份:
    2016
  • 资助金额:
    $ 59万
  • 项目类别:
Mass Spectrometric Studies of Thiotemplate Biosynthesis
硫模板生物合成的质谱研究
  • 批准号:
    9240599
  • 财政年份:
    2016
  • 资助金额:
    $ 59万
  • 项目类别:
Mapping and Understanding Production of Natural Products in Fungi
绘制和了解真菌天然产物的生产
  • 批准号:
    10522724
  • 财政年份:
    2016
  • 资助金额:
    $ 59万
  • 项目类别:
Mass Spectrometric Studies of Thiotemplate Biosynthesis
硫模板生物合成的质谱研究
  • 批准号:
    9905491
  • 财政年份:
    2016
  • 资助金额:
    $ 59万
  • 项目类别:
National Resource for Translational and Developmental Proteomics
国家转化和发育蛋白质组学资源
  • 批准号:
    9283567
  • 财政年份:
    2015
  • 资助金额:
    $ 59万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 59万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 59万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 59万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 59万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了